Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.
This practice parameter describes treatment with stimulant medication. It uses an evidence-based medicine approach derived from a detailed literature review and expert consultation. Stimulant medications in clinical use include methylphenidate, dextroamphetamine, mixed salts of amphetamine, and pemoline. They carry U.S. Food and Drug Administration indications for the treatment of attention-deficit hyperactivity disorder.
Greenhill
L L
LL
Pliszka
S
S
Dulcan
M K
MK
Bernet
W
W
Arnold
V
V
Beitchman
J
J
Benson
R S
RS
Bukstein
O
O
Kinlan
J
J
McClellan
J
J
Rue
D
D
Shaw
J A
JA
Stock
S
S
Kroeger
K
K
D000293:Adolescent; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D000075202:Contraindications; D019091:Critical Pathways; D019317:Evidence-Based Medicine; D006801:Humans
D000697:Central Nervous System Stimulants